William K. Heiden
President and Chief Executive Officer
pharmaceutical and biotechnology
United States of America
William Heiden is an experienced pharmaceutical and biotechnology executive who has been chief executive officer of AMAG since May 2012 and served as president from May 2012 through April 2015. Mr. Heiden joined AMAG from GTC Biotherapeutics, Inc. (now rEVO Biologics, Inc.), where he was president and chief executive officer from 2010 to 2012 and chairman of the board of directors from 2007 to 2013. From 2004 to 2008, Mr. Heiden was the president and chief executive officer and a member of the board of directors of Elixir Pharmaceuticals. Prior to that, Mr. Heiden served as president and chief operating officer of Praecis Pharmaceuticals Incorporated (now GlaxoSmithKline plc). Mr. Heiden also held various positions of increasing responsibility at Schering-Plough Corporation (now Merck & Co.), including managing a number of businesses in the United States, Europe and Canada. He currently serves on the board of directors for Atara Biotherapeutics, Inc. Mr. Heiden holds a Bachelor of Arts degree from the University of Florida, a Master of Information Management from the University of Louvain, and a Master of Business Administration from Cornell University’s Johnson Graduate School of Management.
Digoxin Immune Fab, Regenerative Medicine